2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2719

Performance of the New ACR Criteria in Systemic Sclerosis: A Multicenter Study
Abstract Number: 2535

Performance of the Ocular Staining Score (OSS) Vs. the Van Bijsterveld Score in the Assessment of Sjögren’s Syndrome-Related Keratoconjunctivitis Sicca
Abstract Number: 731

Performance of the Old ACR and the New ACR-EULAR Systemic Sclerosis Classification Criteria in Patients with Limited Cutaneous Disease: Effect on the Ascertainment of Severe Pulmonary Arterial Hypertension
Abstract Number: 1234

Periodic Fever Syndromes in an Academic Medical Center
Abstract Number: 1426

Periodontal disease and Clinical Activity of Rheumatoid Arthritis Patients
Abstract Number: 1393

Periodontal Disease and Its Impact on Structural Joint Damage in a Rheumatoid Arthritis Peruvian Population
Abstract Number: 603

Periostin May Have a Role in Ankylosing Spondylitis and It Is Associated with Wnt Signalling Pathway Regulators
Abstract Number: 1719

Periostin May Promote Productin of Extracellular Matrix By Modulating TGF-β Signaling in Human Skin Fibroblasts
Abstract Number: 799

Peripheral Arterial Disease in Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Abstract Number: 1698

Peripheral Blood Eosinophil Counts Increase in Patients with Systemic Sclerosis and Associated with Its Disease Severity
Abstract Number: 1754

Peripheral CD5⁺b-Cells in ANCA-Associated Vasculitis
Abstract Number: 1853

Persistence and Predictors of Biologic TNFi Therapy Among Biologic naïve Psoriatic Arthritis Patients in a US Registry
Abstract Number: 1569

Persistence of Biologic Therapy in Psoriatic Disease: Results from the Psoriasis Longitudinal Assessment and Registry
Abstract Number: 1594

Persistence of Low Disease Activity after Tumor Necrosis Factor Inhibitor Withdrawal in Patients with Psoriatic Arthritis
Abstract Number: 2494

Persistence on Single Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis Is Extremely Rare

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].